Patent · US Active

Substituted cinnolines as inhibitors of LRRK2 kinase activity

US9884828B2 · kind B2 · utility

0Cited by

3References

23Claims

0Family size

Assignee

IMAGO PHARMACEUTICALS, INC. · US

Inventors

Danielle Aubele · Burlingame, US
Albert W. Garofalo · South San Francisco, US
Simeon Bowers · Oakland, US
Anh Truong · Burlingame, US
Xiaocong Michael Ye · Palo Alto, US
Maurizio Franzini · Cambridge, US
Marc Adler · Orinda, US
R. Jeffrey Neitz · San Francisco, US
Gary Probst · San Francisco, US

Key dates

Filing date	May 21, 2012
Grant date	Feb 6, 2018
Priority date	—
Expiry date	Feb 1, 2035

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D417/04
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

The present invention provides compounds having a structure according to Formula I: (I) or a salt or solvate thereof, wherein R1, R2, R3 and R4 are defined herein. The invention further provides pharmaceutical compositions including the compounds of the invention and methods of making and using the compounds and compositions of the invention, e.g., in the treatment and prevention of various disorders, such as Parkinson's disease.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.